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Th e health-related quality of life (HRQOL) of patients with chronic kidney disease (CKD) has recently been the focus of much attention. 1 The association of impaired HRQOL measures with higher hospitalization and mortality rates is well documented. 2, 3 And, importantly, HRQOL measures are being viewed as valid end points of clinical trials involving the care of CKD patients. 1, 4 It is in fact now mandated that HRQOL be monitored in the United States as part of the conditions of coverage for end-stage renal disease (ESRD) patients by the Centers for Medicare & Medicaid Services. 1 Th e high incidence of clinical depression and the striking presence of depressive symptoms in CKD patients have also been the subject of several recent reviews and studies. 3, 5 Th ese investigations have primarily focused attention on the patient with ESRD. 3, 5 Th e remarkably high prevalence of CKD in the general population has been emphasized and is provoking much discussion among nephrologists about how to coordinate the care of these patients to slow the progression of their CKD, reduce their high cardiovascular complication rate, manage the various CKD-specifi c comorbidities (for example, anemia, CKD -mineral and bone disorder, hypertension), provide education concerning CKD and the implications of ESRD therapy, and improve the overall medical care of these complex patients. But the impairment of the HRQOL of CKD patients not on dialysis has only recently begun to be systematically evaluated. 6 -8 6 Hedayati et al. performed structured interviews with 272 CKD patients (the majority stage 3 and stage 4) and noted a 21 % incidence of clinical depression. 7 And the paper by Fischer et al. 8 in this issue of Kidney International underscores the remarkably high incidence of depressive symptoms in CKD patients -26 % of 628 African-American patients enrolled in the African American Study of Kidney Disease and Hypertension Cohort Study had Beck Depression Inventory (BDI) scores greater than 14 at the time of enrollment. It is important to remember that establishing a diagnosis of clinical depression requires that a structured interview be performed to fulfi ll the standard Diagnostic and Statistical Manual of Mental Disorders IV criteria for a clinical depression; such interviews were not performed in the study by Fischer et al. 8 But a prior study by Hedayati et al. in which CKD patients not on dialysis completed a BDI questionnaire and then participated in a structured interview established that a BDI score of 11 or greater had 89 % sensitivity and 88 % specifi city for diagnosing clinical depression. 7 Th us, it is likely that the vast majority of the patients studied by Fischer et al. 8 would in fact meet the criteria for a clinical depression if interviewed -although it would be of interest to confirm that Hedayati ' s fi ndings were substantiated in this study population.
Th e fi ndings of Fischer et al. 8 are in some ways not surprising. Th e high incidence of depressive symptoms in patients with chronic disease is well documented. For example, in a large World Health Organization study examining the incidence of self-reported depressive symptoms, nearly 25 % of patients with two or more medical conditions (as many CKD patients have) reported having depressive symptoms. 9 Why then are these fi ndings so important? First, the study directs attention to the psychosocial diffi culties of the patient with CKD and obligates us to expand our view of developing strategies for the management of these patients. The well-documented association of depressive symptoms with adverse medical outcomes, vascular disease, poor compliance, and infl ammation underscores the adverse impact that this problem can have on the outcomes of CKD patients. 1 Second, the study draws our attention to the association between depressive symptoms and other HRQOL measures, including satisfaction with life and selected domains on the Short Form (36) Health Survey (Mental and Physical Health Component Scores). And, third, the study demonstrates an association between low income and unemployment and depressive symptoms; that is, the disadvantaged are the ones most in need of support and intervention.
As attention is now being increasingly focused on the comprehensive management of CKD patients not on dialysis, it is clear that an expanded view needs to be taken of how this care is organized ( Figure 1 ). We must provide more than just detailed management of the complex medical complications presented by these patients. Structured education programs are being developed and integrated into standard CKD care to enable patients to become active and informed participants in their treatment program. The importance of this education in improving patient compliance and medical outcomes and facilitating the transition to ESRD care is now recognized. Previous studies have clearly indicated that patients receiving traditional routine care in the United States and Canada do not develop an understanding and knowledge of the basics of CKD care and modality options for ESRD. 10 And it is not possible during routine physician visits to provide adequate information to permit patients to understand the complexities of dietary variables that may impact on their outcomes; dieticians need to directly participate in patient care. In the United States, the Centers for Medicare & Medicaid Services have now agreed to provide fi nancial support for both of these arenas (dietary support and patient education), following the lead of other countries that have had more enlightened views of coordinating and providing more comprehensive healthcare services. Moreover, the paper by Fischer et al. 8 draws our attention to the psychosocial problems of patients with CKD. This arena also needs to be addressed to permit us to off er thorough and optimal care to these patients. Addressing the psychosocial problems of patients and their families needs to be incorporated into the routine care of CKD patients. Additional support needs to be provided to permit this to occur. Th e importance of addressing these psychosocial problems in terms of improving medical outcomes, reducing costs, and enhancing patients ' HRQOL needs additional emphasis and attention.
Lessons from the care of ESRD patients in this regard may be helpful. A high incidence of clinical depression in ESRD patients is well documented. 1, 5 Various treatment options have now been shown to be helpful in reducing depressive symptoms. 1, 5 Th ese options include both pharmacological and non-pharmacological therapies, including cognitive-behavioral therapy, exercise, and modifi cations in the dialysis treatment regimen. 1, 5 It has been proposed that ESRD patients routinely be screened with validated questionnaires inquiring about depressive symptoms and that those patients with scores above certain predetermined values have direct interviews to screen for clinical depression. 1, 5 Appropriate treatment options can then be discussed with the patient. Could a similar algorithm be developed for CKD patients?
Fischer et al. 8 emphasize that it is the fi nancially disadvantaged who need the most support -perhaps sending a message to health-care policy makers in the United States about the need for healthcare reform. It is this population (the unemployed and low-wage earners) who oft en lack proper health insurance and thus are deprived of the health care that they so need. We must ask ourselves to what extent the high incidence of ESRD in these groups of patients refl ects their limited access to care rather than a genetic predisposition.
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Th erapeutic interventions are generally based on an evaluation of clinical data, diagnostic information, and availability of the therapy and ancillary resources. Th ere is an increasing appreciation that the timing of therapy is an important determinant of outcomes, particularly if the intervention targets a specifi c mechanism or pathway involved in the disease process. For instance, management of acute chest pain syndromes and stroke emphasizes early interventions within a few hours from the event. Th erapy is targeted to mitigate the eff ects of platelet adherence and activation, which have been implicated in the development of the ischemic injury. Th ese strategies have dramatically altered outcomes and resulted in improved survival and have further demonstrated the time-dependent relationship of the benefi t. On the basis of these observations, it is apparent that interventions based on ' windows of opportunity ' coupled with targeted therapy are an important construct for managing diseases. However, in kidney disease, these approaches are applied only in a limited fashion. Unlike myocardial infarction and stroke, kidney disease is largely asymptomatic, and kidney injury may be discovered only late in the course. Consequently, precise timing has usually not been a major focus, particularly in chronic kidney disease (CKD), since the progression generally occurs over weeks and months. Additionally, although several targets have been identifi ed, few are actually used -for example, angiotensin-converting enzyme inhibitors for slowing progression. Similarly, in acute kidney injury (AKI), a sense of therapeutic nihilism has prevailed, with no clear therapeutic options
